A phase I study of CPT-11 plus chronomodulated (chrono) 5-Fluorouracil (5-FU) and L-folinic acid (FA) in advanced colorectal cancer (ACC) patients

被引：0
|
作者：
Garufi, C
Tampellini, M
D'Attino, RM
Nistico, C
Aschelter, AM
Pugliese, P
Caterino, M
Giunta, S
Faranda, A
Tropea, F
Comis, S
Dogliotti, L
Terzoli, E
机构：
[1] Ist Regina Elena, I-00161 Rome, Italy
[2] Univ Turin, Turin, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
178P
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [21] Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    Van Cutsem, E
    Cunningham, D
    Huinink, WWT
    Punt, CJA
    Alexopoulos, CG
    Dirix, L
    Symann, M
    Blijham, GH
    Cholet, P
    Fillet, G
    Van Groeningen, C
    Vannetzel, JM
    Levi, F
    Panagos, G
    Unger, C
    Wils, J
    Cote, C
    Blanc, C
    Hérait, P
    Bleiberg, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 54 - 59
  • [22] Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer
    Fujishima H.
    Kikuchi I.
    Miyanaga O.
    Ueda A.
    Baba E.
    Mitsugi K.
    Harada M.
    Nakano S.
    International Journal of Clinical Oncology, 2004, 9 (2) : 92 - 97
  • [23] A dose finding study of biweekly administration of irinotecan (CPT-11), 5-fluorouracil (5-FU) and levofolinic acid (I-LV) in colorectal cancer
    Casaretti, R
    Catalano, G
    Comella, P
    De Vita, F
    Avallone, V
    Gravina, A
    Orditura, M
    Comis, S
    Faranda, A
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 68 - 68
  • [24] 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) versus CPT-11 followed by 5-FU/LV at relapse in patients with advanced colorectal carcinoma. Phase III randomized study
    Tsavaris, N.
    Kosmas, C.
    Skopelitis, E.
    Papadoniou, N.
    Polyzos, A.
    Zografos, G.
    Diamartis, N.
    Ntokou, A.
    Tsaousi, S.
    Sarantonis, I
    Adoniou, E.
    Gryniatsos, J.
    Felekouras, E.
    Papalambros, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 81 - 81
  • [25] Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma -: A phase I study
    Garufi, G
    Dogliotti, L
    D'Attino, RM
    Tampellini, M
    Aschelter, AM
    Pugliese, P
    Perrone, M
    Nisticó, C
    Comis, S
    Terzoli, E
    CANCER, 2001, 91 (04) : 712 - 720
  • [26] Phase I-II study of gemcitabine (GEM) plus fluorouracil (5-FU) and folinic acid (FA) in patients with advanced breast cancer (ABC).
    Simoncini, E
    Ferrari, VD
    Marpicati, P
    Montini, E
    Rangoni, G
    Marini, G
    ANNALS OF ONCOLOGY, 2000, 11 : 42 - 42
  • [27] A phase I-II trial of chronomodulated chemotherapy (CMC) of metastatic breast cancer (MBC) with mitoxantrone (MX), 5-fluorouracil (5-FU) and folinic acid (FA)
    Depres-Brummer, P
    Mahjoubi, R
    Zidani, R
    Llory, JF
    Bertheault-Cvitkovic, F
    Vannetzel, JM
    Levi, F
    ANNALS OF ONCOLOGY, 1998, 9 : 22 - 22
  • [28] 5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)
    Andric, Z.
    Murtezani, Z.
    Kovcin, V
    Gutovic, J.
    Kostic, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 67
  • [29] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
  • [30] Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients
    Garufi, C
    Brienza, S
    Pugliese, P
    Aschelter, AM
    Bensmaine, MA
    Bertheault-Cvitkovic, F
    Nisticò, C
    Giunta, S
    Caterino, M
    Giannarelli, D
    Cosimelli, M
    Lévi, F
    Terzoli, E
    ANTI-CANCER DRUGS, 2000, 11 (06) : 495 - 501
12345